Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thanks for the update on that.
glad he called back.
I cannot believe that he still has that Wall twp plant open since 1991...
it is one of the greatest mysteries of our time- not a product sold and still open 31 years later.
true..but maybe 10% of relevance it had maybe 10 years ago
break out boards and ihub do not really hold any value or meaning any more..
but it's stiull good to check in every now and then...
that is hardly a pump.. not even close.
previous pumps would have like 100 posts on there all within an hour..
same here.. been here at least 5 times over past 5 or so years.
I will admit though that last few times this occurred there was some kind of news/filing/pump that instigated the early part of the rise.
this time seems different.
we shall see..
even though I have an certain amount of shares from way way back.. your scenario seems 99.87% likely..
BUT.. I will have to say that it is bizarre that stock wasn't revoked years ago.
Don't know about going to the grave wondering..just one of those little mysteries in life - such why some people hang around a certain almost dormant stock on the otc and pinks for years and years when they supposedly are not invested.
not just this stock but many many others .. it is a commonality almost.
reasons must be varied but similar at the same time.
Well if you are ever in San Diego look me up.. have a beer..
as far as the difference between the dollar stores.. maybe he pulled a Joe? who knows- who cares.... a little slip of the tongue and pen.
it is interesting none the less... always wanted to know what lies beneath..
and the post gets removed...
pretty funny.
keep up the good work..
You guys still here...?
Don't be too scardy of what is coming..
well it is hard to get volume when I cant trade it in the USA..
still have my shares from long long ago...
I also had a small fee on Etrade and merrill..
he filed the split on the nevada silver flume corporate site.
the good news is that he had zero reason to do this unless he has a plan for the resurrection in the near future.
IMO if he did it his plans are for straight to the Nasdaq.
would need a miracle for that to happen (major deal signed/financing and underwriting by major firms)
so $3-5 per share to max of $10 in this "miracle world.."
I am still counting this as a zero but have not taken the tax loss.
Should easily get back to its $5 IPO price within coming weeks.
I have missed you Hulk.
maybe making a comeback?
It is a big if..
the PP is for like pennies..10 mill is like a mcd happy meal nowadays.
it isnt much but I really think they are looking at something much much larger. like a major firm to back and take them public.
at least that is what he may be attempting.
maybe send a email or phone them and see if you get a response.
assist@coatesengine.com
report back...
seems he has something big lined up via other sources.
I still wouldn't hold your breath. It is all about lining up the equity deal that takes COTE public again. much has to fall in place. ..this time on the NQ
News 7 Billion in orders...
COATES INTERNTIONAL, LTD. AND ADVANCED HYDROGEN POWER, LTD. HAVE RECEIVED ORDERS FOR THEIR CSRV® HYDROGEN H2 INDUSTRIAL ELECTRIC POWER GENERATORS AMOUNTING TO $7,125,000,000
Wall Township, NJ – (Globe Newswire – February 24, 2022) For Immediate Release: Coates International, Ltd. (COTE) and Advanced Hydrogen Power, Ltd. (the “Companies”) have received firm orders amounting to $7,125,000,000 USD for their CSRV® Hydrogen (H2) Electric Power Industrial Generators including the H2 Reactors. These units are coupled together as one power unit. The R&D on these new technologies is complete. The first production models are being built now. The 100 K.W., 150 K.W. and 200 K.W. units are expected to start shipping out to customers this year. 1 M.W. units are expected to start shipping out to customers in 2023. We believe that these CSRV® Hydrogen (H2) Industrial Electric Power Generators including the H2 Reactor are the cleanest and lowest emission power units in the world and will help resolve global warming.
Company President and CEO, George J. Coates, EE ME, comments: “A lot of companies are announcing that they are going to do this and that with H2. Here at Coates International, Ltd. we have done it successfully with our CSRV® Engines and Hydrogen Reactors operating successfully in our New Jersey Plant. Now it’s time for our companies to get into full production and get products out to our customers. I would like to point out the fact that Gaseous Hydrogen H2 is an extremely minute atom and will pass through the stem of a standard poppet valve and fill up the engine housing with Gaseous Hydrogen that can explode the engine at any time. This cannot happen with the CSRV® H2 Engines as there are no passages from the CSRV® system into the engine housing so we have the only engines in the world that are safe to operate on Gaseous Hydrogen (H2). Our Sequential H2 Fuel Injection System injects the H2 gas directly into the cylinder. We have designed a proprietary blow back system on our Hydrogen Reactors and our CSRV® Industrial Hydrogen H2 Systems are the safest in the world.”
Company management is in talks with a number of business groups regarding the companies’ expansion into production.
1st halt possibility incoming....
15 .. Breaking out...
we are in early stages of the Squeeze..
could see more of a squeeze/halt with volume increase over 100..
Trump has released 2 messages today about Truth Social..
this is very good..
it basically means the launch is on track.
also, because his "messages" are pretty much censored by social media:
this means most people have no Idea about it.. and I guarantee you 99% have no Idea what a DWAC is..
this is super bullish AF..
we are climbing already.. and the masses have no clue yet..
Masses have no clue+shorts+freedom+launch coming+ticker strength= MEGA BOOM..!
NEWS Hydrogen is the World’s Cleanest and Most Abundant Energy Source. Here at Our Research Laboratory in New Jersey, USA we Are Working on a System That Produces the Hydrogen Gas Totally Free of Cost.
February 02, 2022 06:00 ET | Source: Coates International
...
Wall Township, NJ, Feb. 02, 2022 (GLOBE NEWSWIRE) -- For Immediate Release: Coates International, Ltd. and Advanced Hydrogen Power, Ltd. (the “Companies”). The Research Scientist Team have been working on a completely new system that will produce Gaseous Hydrogen totally free at no cost whatsoever. Hydrogen, at present, is produced from energy derived from the CSRV® Engine Electric Power Generator. For instance, a 100 KW CSRV® Electric Power Generator would use 1 KW to produce the H2 fuel that is used to operate the CSRV® Generator Set. Now we believe that our new and totally separate system shall produce the Gaseous Hydrogen (H2) totally free of any cost or energy from the CSRV® Generator Set. This means that our CSRV® H2 Electric Power Generators will produce electric power at almost no cost and produce no harmful emissions. This is the first of its kind in the world and will revolutionize green energy and help combat climate change.
Company President and CEO, George J. Coates, EE ME comments: “Lots of people and companies are working on Hydrogen projects around the world because Hydrogen is the cleanest fuel in the world. Our H2 Reactor produces Hydrogen from ordinary water or sea water producing gaseous Hydrogen. However, most companies are producing liquid H2 which is produced with very high pressure and costs approximately $10.00 per gallon. A lot of reports and comments state that it is not dangerous. (They are wrong.) Hydrogen storage is highly dangerous. H2 in any form is highly dangerous. Static electricity and air can set off a major explosion even if the flames rise upward. The explosion can blow a building down and kill many people. For instance, we have tested Gaseous H2 on Poppet Valve Engines and found that the H2 gets past the poppet valve stems into the engine housing filling it up with Gaseous H2 that will cause a major explosion of the whole engine; it would be catastrophic. This cannot happen with the Coates CSRV® engines as there are no passage ways from the CSRV® valve system to the engine housing. We have designed blow back safety devices that prevent any detonation of H2. Our H2 Reactor and CSRV® Industrial Electric Power Generator-Sets use up the gaseous Hydrogen as it is produced. It is used as fuel to power the CSRV® Electric Power Generator-Sets. We do not store Gaseous Hydrogen (H2).
We also designed and developed our own H2 Injection System for Gaseous Hydrogen. We have many major breakthroughs and a number of new Patents in the process.
We believe this is the most Clean Green Electric Power H2 Energy in the world. Orders are in place and production will start very soon. Negotiations with various companies and entities are ongoing. More updates will be forthcoming.”
better get out that Clunker chart fast...LOL
80... 100 next..
it is pretty sad actually. Big boys always still in control and that will never change..
News Sorrento has Omicron Killer...but...well ..you know the deal
Will anyone care? Algos all set to fade in 3..2..1...
Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron
January 28, 2022 at 9:00 AM ESTDownload PDF
STI-1558, a novel oral Mpro inhibitor, effectively inhibits Omicron virus entry and replication in cells.
STI-1558 is orally bioavailable with improved human liver microsomal stability to avoid using Ritonavir as a pharmacokinetic enhancer in humans.
SAN DIEGO, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced its late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits Omicron virus entry and replication in cell-based assays.
The world is experiencing a huge wave of infection with the Omicron variant of SARS-CoV-2, and current vaccines and EUA-approved antibodies offer diminished protection against Omicron transmission and infection. STI-1558 is an oral Mpro inhibitor which has demonstrated in preclinical studies broad-spectrum anti-SARS-CoV-2 activity when tested for activity against the original SARS-CoV-2 strain and all previous predominant variants of concern (VOCs).
STI-1558’s antiviral activity against Omicron has also been tested in a cell-based neutralization assay. In VeroE6 cells challenged with Omicron variant, STI-1558 alone (without efflux inhibitor) showed significant antiviral activity with an EC50 value of 360 nM, equivalent activity to that seen against the Delta variant (EC50 value, 370 nM). Notably, in an Omicron S protein-mediated pseudovirus entry assay, STI-1558 effectively inhibited pseudovirus entry into cells, whereas EUA-approved nirmatrelvir showed no inhibition. Particularly, STI-1558 showed improved human liver metabolic stability as compared to nirmatrelvir, and its oral bioavailability does not depend on the ritonavir co-administration. Without the need to co-administer Ritonavir, STI-1558 potentially avoids significant adverse drug-drug interactions.
“With Omicron becoming a globally dominant variant of SARS-CoV-2 in such a short period of time, we are focused on developing an effective therapeutic strategy for fighting the Omicron variant and future variants of concern, and most importantly, for preventing or overcoming drug-resistance. Sorrento continues its commitment to develop and deliver effective anti-COVID therapies to save patient lives and end the pandemic,” stated Dr. Henry Ji, Chairman and CEO of Sorrento.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG™, COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™ and COVISTIX™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia (PHN). RTX has cleared for Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. SEMDEXA announced highly statistically significant positive top-line results from its Phase III Pivotal Trial C.L.E.A.R Program for its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica). ZTlido® was approved by the FDA on February 28, 2018.
NEWS -PANCREATIC CANCER- Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies
Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own pancreatic cancer and have an intact immune system.
Historically, 42-days is the median survival produced by a 4-drug combination: 2 chemotherapies and two immunotherapies in the same genetic pancreatic cancer mouse model.
"This data highlights why we are excited to collaborate with BeiGene on our planned 2022 Phase 1b/2a combination trial of IMX-110 + BeiGene anti-PD-1 tislelizumab in advanced solid tumors," said Ilya Rachman, CEO of ImmixBio. "We believe this upcoming combination clinical trial will allow us to expand into multiple oncology indications rapidly."
In 2022, the Company plans to commence combination IMX-110 + BeiGene Ltd (NASDAQ: BGNE) anti-PD-1 tislelizumab Phase 1b/2a clinical trial in advanced solid tumors.
Related: Immix's Lead Program Shows 50% Response Rate In Resistant Cancer In Animal Study.
The FDA has approved orphan drug designation for IMX-110 for soft tissue sarcoma. Additionally, the FDA has approved rare pediatric disease designation to IMX-110 for rhabdomyosarcoma.
dude its on the SEC site
search :cryptyde or tyde
https://www.sec.gov/edgar/browse/?CIK=1892492&owner=exclude
Dear Future Cryptyde, Inc. Stockholder:
On behalf of Cryptyde, Inc., it is my great privilege to welcome you as a future stockholder of our company. Following our separation from Vinco Ventures, Inc., we will operate as an independent, publicly traded and growth-oriented company. We plan to have three initial business lines, Web3 (decentralized internet) products, Bitcoin mining services, and consumer packaging. Through our Web3 products business line, we will seek to acquire and build brands that use decentralized blockchain technologies in a variety of consumer facing industries, such as music, movies, digital art, ticketing and event services, and gaming. Our Bitcoin mining services will aim to make Bitcoin mining accessible to consumers previously priced out of the area. Additionally, we will continue to grow the 50 plus year history of our consumer packaging business.
We intend to expand through both organic growth and strategic acquisitions. We hope to acquire and create Web3 products that are met with customer satisfaction and build customer loyalty. We plan to continue developing our Bitcoin mining services by growing or seeking to grow a customer base of both existing Bitcoin miners and those who have not yet entered the space. We also intend to grow and evolve our consumer packaging business to meet the demands of today’s e-commerce businesses, as well as customers in other industries.
Vinco Ventures, Inc. is expected to continue its operations other than the three business lines that will be part of Cryptyde. We expect Vinco Ventures, Inc. to continue its programs designed to help inventors share and develop their products. Historically, Vinco Ventures, Inc. has conducted programs for inventors under its Edison Nation brand. Recently, Vinco Ventures, Inc. has integrated its inventor focused programs into its Lomotif App and developed Everyday Edisons, which is expected to put inventors in front of industry experts.
We invite you to learn more about our company by reading the enclosed information statement, which details our strategy and plans for near and long-term growth to generate value for our stockholders. We are excited about our future as an independent company, and we look forward to your support as a Cryptyde, Inc. stockholder as we begin this new and exciting chapter.
Sincerely,
Brian P. McFadden
President and Chief Executive Officer
Cryptyde, Inc.
looks like a Squeeze is starting very early stages...
Large volume on the increase.. rising...
DWAC/TMTG job posts on their website
https://careers.tmtgcorp.com/
interesting descriptions if you click on the job...
I do agree on the Covi stix.. there is always money to be made on testing and stocking up for any "future new variants" (or whatever they are).
focus neeeds to be on the big picture..
great news - it seems but nothing happens except downward pressure.
it is tough to deal with.
IMO the covid stuff is basically over..
COVID is over.
Omnicron is a zero..
focus on the pain/cancer treatment in pipe line.
good luck ..we need it.